Introduction
Achalasia is traditionally managed as a pure motility disorder, and treatment success is usually judged by technical outcomes—lower oesophageal sphincter (LES) disruption, improved emptying on timed barium esophagram (TBE), and manometric changes. Yet, many clinicians recognise a frustrating reality:
Some patients continue to report dysphagia, chest pain, and poor quality of life despite objectively successful treatment.
This study addresses an often-overlooked question:
Do psychological factors—specifically oesophageal hypervigilance and anxiety—predict how patients feel after achalasia treatment?
The clinical problem
Persistent symptoms after pneumatic dilation, POEM, or Heller myotomy are commonly attributed to:
incomplete myotomy,
reflux, or
residual obstruction.
However, these explanations do not fully account for patients who have:
good oesophageal emptying,
acceptable manometry, and
no major structural issues—yet remain highly symptomatic.
This raises the possibility that central symptom processing, not oesophageal mechanics alone, influences outcomes.
What the authors studied:
The investigators evaluated achalasia patients after definitive therapy and assessed:
Oesophageal Hypervigilance and Anxiety using the EHAS (a validated scale),
Oesophageal-specific quality of life (E-QOL / NEQOL),
Objective measures such as TBE.
They then examined whether psychological measures predicted post-treatment symptoms and quality of life independent of objective oesophageal findings.
Key findings clinicians should understand
1) Hypervigilance and anxiety strongly predict patient-reported outcomes
Higher scores on oesophageal hypervigilance and anxiety were associated with:
worse post-treatment symptoms, and
poorer oesophageal-specific quality of life.
This relationship persisted even when objective measures were acceptable.
2) Objective success does not guarantee symptomatic success
Patients with good TBE results and technically successful interventions still reported poor outcomes if hypervigilance and anxiety were high.
3) Achalasia outcomes are not purely mechanical
These findings support a brain–esophagus interaction, where heightened symptom monitoring, fear of symptoms, and anxiety amplify symptom perception after treatment.
Why this matters in clinical practice
Explains “unexplained failure”
This study helps explain why some patients remain dissatisfied after technically successful achalasia therapy.
Pre-treatment counseling
Identifying high hypervigilance/anxiety before intervention may:
set realistic expectations,
reduce post-treatment dissatisfaction.
Post-treatment management
Persistent symptoms should not automatically trigger:
repeat dilation,
redo POEM,
or escalation to surgery.
In selected patients, psychological or behavioural interventions may be more appropriate.
Practical take-home messages
If post-treatment symptoms do not match objective findings, consider hypervigilance and anxiety.
Use validated tools (like EHAS) to identify at-risk patients.
A multidisciplinary approach—including behavioural therapy, reassurance, and symptom education—may improve outcomes more than additional procedures.
Bottom-line takeaway:
In achalasia, patient outcomes are driven not only by oesophagal emptying, but also by how symptoms are perceived and processed. Addressing oesophagal hypervigilance and anxiety is essential to improving real-world treatment success.
One-line GastroAGI takeaway
Successful achalasia treatment requires treating both the esophagus and the brain.